VELOXIS PHARMACEUTICALS A/S — Credit Rating and Financial Key Figures
CVR number: 26527767
Gdanskgade 18, 2150 Nordhavn
info@veloxis.com
www.veloxis.com
Income statement (kUSD)
2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | 45 964.00 | 45 335.00 | |||
| Other operating income | 1 212 467.00 | ||||
| Gross profit | 45 964.00 | 45 335.00 | |||
| Costs of marketing | - 377.00 | - 214.00 | - 308.00 | ||
| Other operating expenses | -30 291.00 | -1 327.00 | -8.00 | ||
| EBIT | 15 673.00 | 1 256 475.00 | - 385.00 | - 214.00 | - 308.00 |
| Other financial income | -30.00 | 2 604.00 | 90.00 | 52.00 | 36.00 |
| Interest income | 3 077.00 | ||||
| Other financial expenses | - 245.00 | -1 385.00 | - 158.00 | -18.00 | -8.00 |
| Pre-tax profit | 15 398.00 | 1 257 711.00 | 2 624.00 | - 180.00 | - 280.00 |
| Income taxes | 19 801.00 | - 200 250.00 | - 564.00 | 77.00 | -12 989.00 |
| Net earnings | 35 199.00 | 1 057 461.00 | 2 060.00 | - 103.00 | -13 269.00 |
Assets (kUSD)
2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Intangible rights | 17.00 | 9.00 | |||
| Intangible assets total | 17.00 | 9.00 | |||
| Other tangible assets | 62.00 | 13.00 | |||
| Tangible assets total | 62.00 | 13.00 | |||
| Holdings in group member companies | 73 412.00 | ||||
| Investments total | 73 412.00 | ||||
| Deferred tax assets | 50 205.00 | ||||
| Long term receivables total | 50 205.00 | ||||
| Inventories total | |||||
| Current trade debtors | 170.00 | 225.00 | 203.00 | ||
| Current owed by particip. interest comp. | 1 300 017.00 | ||||
| Prepayments and accrued income | 368.00 | 182.00 | 162.00 | 145.00 | 124.00 |
| Current other receivables | 308.00 | 310.00 | - 162.00 | - 222.00 | - 201.00 |
| Current deferred tax assets | 64.00 | 77.00 | 77.00 | ||
| Short term receivables total | 676.00 | 1 300 573.00 | 170.00 | 225.00 | 203.00 |
| Cash and bank deposits | 14 750.00 | 3 546.00 | 3 715.00 | 3 142.00 | 3 123.00 |
| Cash and cash equivalents | 14 750.00 | 3 546.00 | 3 715.00 | 3 142.00 | 3 123.00 |
| Balance sheet total (assets) | 139 122.00 | 1 304 141.00 | 3 885.00 | 3 367.00 | 3 326.00 |
Equity and liabilities (kUSD)
2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Share capital | 26 257.00 | 26 422.00 | 57.00 | 57.00 | 57.00 |
| Share premium account | 221 079.00 | 329 672.00 | |||
| Other reserves | -4 297.00 | ||||
| Retained earnings | - 140 542.00 | - 109 640.00 | 764.00 | 2 824.00 | 2 721.00 |
| Profit of the financial year | 35 199.00 | 1 057 461.00 | 2 060.00 | - 103.00 | -13 269.00 |
| Shareholders equity total | 137 696.00 | 1 303 915.00 | 2 881.00 | 2 778.00 | -10 491.00 |
| Non-current liabilities total | |||||
| Current trade creditors | 3.00 | ||||
| Current owed to group member | 168.00 | 400.00 | 539.00 | 811.00 | |
| Short-term deferred tax liabilities | 1 199.00 | 564.00 | 12 989.00 | ||
| Other non-interest bearing current liabilities | 224.00 | 58.00 | 40.00 | 50.00 | 17.00 |
| Current liabilities total | 1 426.00 | 226.00 | 1 004.00 | 589.00 | 13 817.00 |
| Balance sheet total (liabilities) | 139 122.00 | 1 304 141.00 | 3 885.00 | 3 367.00 | 3 326.00 |
Try the full version of our system for free
- Professional credit risk reports
- Create your own estimates for any company
- Valuation analysis
- All 400,000+ Danish companies
- See instructions
... and more!
No registration needed.